Trial finds Repatha outperforms ezetimibe
STAT says a real-world-evidence trial favored the injectable cholesterol drug and describes a 20% reduction in heart attack risk.
Loading… Բեռնվում է…
STAT says a real-world-evidence trial favored the injectable cholesterol drug and describes a 20% reduction in heart attack risk.
The cholesterol drug evolocumab, sold as Repatha, outperformed ezetimibe in a new trial based on real-world evidence, STAT said. Its headline describes a 20% reduction in heart attack risk.
Cardiologists consider both drugs when statins are not enough to reduce LDL cholesterol, often called “bad” cholesterol because it can clog the arteries supplying the heart. Both medicines have been approved for years.
Amgen’s Repatha is injected and blocks a protein called PCSK9 from binding to LDL receptors on liver cells. This leaves more receptors on liver cells available to remove LDL cholesterol from the blood.
Ezetimibe is taken by mouth and reduces cholesterol absorption in the small intestine. This reduces the cholesterol available to liver cells, leading them to take up more cholesterol from circulation. It is available as a generic drug and was previously sold by Merck as Zetia.
The accessible portion of STAT’s article does not give the trial’s size, absolute heart attack rates, follow-up duration or methods. Those details would help readers assess the reported difference in risk.
The inspectorate says joint operations in Armavir’s border zones uncovered a citizen’s illegal withdrawal of Arax River water for irrigation. It also says homemade devices for illegal fishing were removed and seized.
1 min
Prime Minister Nikol Pashinyan says the initiative will develop expertise in educational institutions and laboratories exploring how to integrate superintelligence (SI) with physical objects.
3 min
Each state’s $100 million base allocation is available, but its competitive award is delayed. States must submit budget revisions to the federal agency by 30 November.
2 min